Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked:
Okay, this group in particular, the medical device group, is hated in this market. And I do feel that there is not a lot of money to be made in this one if there’s not a lot to be made in the really, in some really good ones, like Medtronic or ISRG or Boston Scientific.
A stock market graph. Photo by energepic.com
Globus Medical, Inc. (NYSE:GMED) develops healthcare solutions for musculoskeletal disorders. The company provides specialized implants, tools, and biologic materials to help treat spine and orthopedic disorders. In addition, it offers advanced robotic guidance systems, surgical planning software, and nerve monitoring services to assist surgeons during procedures. Invesco Ltd stated the following regarding Globus Medical, Inc. (NYSE:GMED) in its Q4 2025 investor letter:
Globus Medical, Inc. (NYSE:GMED): This medical technology company specializes in musculoskeletal solutions for spine, orthopedic trauma and joint reconstruction. The company has faced issues with recent acquisitions, supply chain issues and weakness in its robotics segment, which together provided an opportunity to purchase the stock at what we saw as an attractive discount to our estimate of intrinsic value.
While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.